secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0000950170-23-019659
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcus Q1 net loss $80M, cash $1.0B; multiple Ph3 domvanalimab trials enrolling
------------------------------------------------------------------------------

- Revenue $25M (up from $18M YoY); net loss $80M vs $68M in Q1 2022.
- Cash, equivalents and securities $1.0B; expected to fund operations into 2026.
- Four Phase 3 and two Phase 2 trials enrolling for domvanalimab combinations in lung and GI cancers.
- AB521 (HIF-2α inhibitor) dose-escalation enrolling 100mg; Phase 2 combo study in ccRCC expected Q3 2023.
- Three new drug candidates advancing to clinic: AB598 (anti-CD39) Q2 2023, AB801 (Axl inhibitor) H2 2023, AB375 (KIT inhibitor) early 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000095017023019659/0000950170-23-019659-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000095017023019659/rcus-20230509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-019659

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer